| Issue Date | Title | Author(s) |
| 2019 | Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors | Wang, Yuetong; Zhang, Jian; Ren, Shengxiang; Sun, Dan; Huang, Hsin-Yi; Wang, Hua; Jin, Yujuan; Li, Fuming; Zheng, Chao; Yang, Liu; Deng, Lei; Jiang, Zhonglin; Jiang, Tao; Han, Xiangkun; Hou, Shenda; Guo, Chenchen; Li, Fei; Gao, Dong; Qin, Jun; Gao, Daming; Chen, Luonan; Lin, Shu-Hai; Wong, Kwok-Kin; Li, Cheng; Hu, Liang; Zhou, Caicun; Ji, Hongbin |
| Jul-2023 | Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations | Wang, Jun; Zhang, Bicheng; Peng, Ling; Liu, Xiufeng; Sun, Jianguo; Su, Chunxia; Wang, Huijuan; Zhao, Zheng; Si, Lu; Duan, Jianchun; Zhang, Hongmei; Li, Mengxia; Zhu, Bo; Zhang, Li; Li, Jin; Guo, Jun; Luo, Rongcheng; Qiu, Wensheng; Ye, Dingwei; Chu, Qian; Cui, Jiuwei; Dong, Xiaorong; Fan, Yun; Gao, Quanli; Guo, Ye; He, Zhiyong; Li, Wenfeng; Lin, Gen; Liu, Lian; Liu, Yutao; Qin, Haifeng; Ren, Shengxiang; Ren, Xiubao; Wang, Yongsheng; Xue, Junli; Yang, Yunpeng; Yang, Zhenzhou; Yue, Lu; Zhan, Xianbao; Zhang, Junping; Ma, Jun; Qin, Shukui; Wang, Baocheng |
| 2011 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Zhou, Caicun; Wu, Yi-Long; Chen, Gongyan; Feng, Jifeng; Liu, Xiao-Qing; Wang, Changli; Zhang, Shucai; Wang, Jie; Zhou, Songwen; Ren, Shengxiang; Lu, Shun; Zhang, Li; Hu, Chengping; Hu, Chunhong; Luo, Yi; Chen, Lei; Ye, Ming; Huang, Jianan; Zhi, Xiuyi; Zhang, Yiping; Xiu, Qingyu; Ma, Jun; Zhang, Li; You, Changxuan |
| Nov-2022 | Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy | Wu, Fengying; Jiang, Tao; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, Lizhu; Feng, Jifeng; Wang, Zhehai; Shu, Yongqian; Shi, Jianhua; Hu, Yi; Wang, Qiming; Cheng, Ying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, LiPing; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; He, Zhiyong; Fang, Jian; Gu, Kangsheng; Dong, Xiaorong; Zhang, Tao; Shi, Wei; Zou, Jianjun; Bai, Xuejuan; Ren, Shengxiang; Zhou, Caicun |
| 2012 | Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCL | Zhou, Caicun; Wu, Yi Long; Liu, Xiaoqing; Wang, Changli; Chen, Gongyan; Feng, Ji Feng; Zhang, Shucai; Wang, Jie; Zhou, Songwen; Ren, Shengxiang; Lu, Shun; Zhang, Li; Hu, Cheng-ping; Luo, Yi; Chen, Lei; Ye, Ming; Huang, Jianan; Zhi, Xiuyi; Zhang, Yiping; Xiu, Qingyu |
| 2016 | Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer | Xu, Naiqing; Fang, Wenfeng; Mu, Libing; Tang, Yanna; Gao, Lei; Ren, Shengxiang; Cao, Dengfeng; Zhou, Lixin; Zhang, Aiqun; Liu, Deruo; Zhou, Caicun; Wong, Kwok-Kin; Yu, Lei; Zhang, Li; Chen, Liang |
